drugset / Trial / NCT06126731
Combination Study of Antibiotics With Enzalutamide (PROMIZE)
Phase 1/2
Recruiting
39 enrolled
Institute of Cancer Research, United Kingdom
Prostate Cancer Foundation · collab
NaSingle-groupOpen-labelTreatment
Summary
PROMIZE is an open-label, multi-centre, single-arm, Phase I/II clinical trial, evaluating the safety, tolerability and anti-tumuor efficacy of an antibiotic combination and enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).
Timeline
- Start
- 2023-11-02
- Primary completion
- 2026-06-30
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amoxicillin | Other / unclassified | 500 mg | Oral |
| Subject | Ciprofloxacin | Small molecule | 500 g | Oral |
| Subject | Enzalutamide | Other / unclassified | 40 mg | — |
| Subject | Metronidazole | Small molecule | 400 mg | Oral |
| Subject | Vancomycin | Other / unclassified | 125 mg | Oral |